mab_id,target,epitope_residues,epitope_sequence,predicted_kd_nm,binding_mechanism,design_approach,cross_reactivity_fl_her2,internalization_prediction,adc_suitability_score,advantages,challenges,development_status
p95-ESM-001,Juxtamembrane stub,615-635,MPIWKFPDEEGACQPCPINC,0.21,Linear epitope mimicry,ESM-based epitope mimicry CDR design,Yes (JM conserved),Moderate (40% at 4h),9.0,Contains PIWKFPD motif for strong complementarity,Limited epitope accessibility near membrane,Pipeline-Predicted
p95-ESM-002,Juxtamembrane stub,615-635,MPIWKFPDEEGACQPCPINC,0.13,Charge complementarity,ESM-based charge complementarity CDR design,Yes (JM conserved),High (50% at 4h),9.0,Optimized charged CDRs for electrostatic binding,Requires validation of charge distribution,Pipeline-Predicted (TOP RANKED)
p95-ESM-003,Membrane-proximal region,640-652,CTHSCVDLDDKGC,0.33,Hydrophobic targeting,ESM-based hydrophobic CDR design,Yes (region conserved),Low (25% at 4h),8.0,Targets hydrophobic patch near membrane,Very close to membrane - steric hindrance,Pipeline-Predicted
p95-ESM-004,Neo-epitope at Met611,611-625,MPIWKFPDEEGACQP,0.20,Neo-epitope specific,ESM-based Met611 neo-epitope recognition,No (neo-epitope specific),High (55% at 4h),9.0,"Specific to p95-CTF611, no FL-HER2 binding",Limited to p95-CTF611 variant only,Pipeline-Predicted
p95-Trastuzumab-Biparatopic,p95 JM + FL-HER2 Domain IV,615-635 + 557-603,Biparatopic dual epitope,0.08,Dual targeting via biparatopic format,Pipeline-designed p95 arm + Trastuzumab Domain IV arm,By design (dual target),Very High (65% at 4h),9.5,Targets both p95+ and FL-HER2+ cells with enhanced clustering,"Complex manufacturing, dual optimization",Pipeline-Predicted (RECOMMENDED)
MCLA-128 (Zenocutuzumab),HER2 Domain II + HER3,HER2: 266-333,N/A (existing mAb),1.5,Bispecific HER2/HER3,Clinical-stage bispecific,Yes (HER2 Domain II),Moderate,7.0,"Blocks HER2/HER3 signaling, clinical data",Does not directly target p95,Phase 2 Clinical
